Aratana Therapeutics Inc. (PETX)

5.37
NASDAQ : Health Technology
Prev Close 5.43
Day Low/High 5.32 / 5.56
52 Wk Low/High 3.67 / 7.67
Avg Volume 447.00K
Exchange NASDAQ
Shares Outstanding 46.84M
Market Cap 254.37M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Activist Fund Engaged Takes New Position in Cross Country Health

Activist Fund Engaged Takes New Position in Cross Country Health

Glenn Welling took a couple new stakes and maintained large stakes at key targets including Rent-A-Center, Hain Celestial and TiVo.

Oversold Conditions For Aratana Therapeutics (PETX)

Oversold Conditions For Aratana Therapeutics (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

Short Interest In Aratana Therapeutics Jumps 11.7%

Short Interest In Aratana Therapeutics Jumps 11.7%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 384,761 share increase in total short interest for Aratana Therapeutics, Inc , to 3,662,877, an increase of 11.74% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

2 Animal Drugmakers Worth a Sniff

2 Animal Drugmakers Worth a Sniff

Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Investors eyeing a purchase of Aratana Therapeutics, Inc stock, but cautious about paying the going market price of $7.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $5 strike, which has a bid at the time of this writing of 20 cents.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Short Interest Expands By 24% For PETX

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 882,728 share increase in total short interest for Aratana Therapeutics, Inc , to 4,576,114, an increase of 23.90% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of PETX November 17th Options Trading

Investors in Aratana Therapeutics, Inc saw new options become available this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of A Class Action On Behalf Of Shareholders Of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline Of April 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc.

PETX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Aratana Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc.

TheStreet Quant Rating: D (Sell)